Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeFUNDINGBioneb Pvt Secures GBP £ 220 Million Capital Commitment From the Gem Group

Bioneb Pvt Secures GBP £ 220 Million Capital Commitment From the Gem Group

October 26, 2020

Bioneb Pvt (Bioneb) announced that it has signed an agreement with GEM Global Yield LLC SCS (“GEM“), the New York-based private alternative investment group to provide Bioneb up to GBP £ 220 million over a 36-month term.

Bioneb will use the funds to continue its research and development of its FDA-approved ultrasonic vibrating mesh drug delivery devices, medical formulations and FDA clinical trials. The company will also increase the manufacturing of the devices at the FDA-approved Vietnamese and Taipei facilities. Simultaneously there will be an increase in the production, distribution, and marketing of the formulations at the Netherlands, Canadian and Californian facilities.

The company will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The company will issue warrants to GEM to purchase up to nine point nine percent (9.9%) of the outstanding common stock of the company on a fully diluted basis. The warrants will have an exercise price per share equal to the pro-rata portion of GBP 300 Million valuation for the company. Bioneb Pvt will pay a fee equal to two percent (2%) of the size of capital commitment within a period of twelve months.

“This agreement with GEM helps to secure funding for continued growth and development of the company as we attempt to bring to market our breakthrough Covid suppressant formulation which is having remarkable results in suppressing and eliminating the Covid Virus if used in the early stages of any infection. The proven results, case studies, time-kill graphs, and curves show that Bioneb’s patent-pending anti-viral formulation eliminates any virus and bacteria when inhaled with the drug delivery device or disbursed into built in environments such as schools, offices or mass transport systems using the same technology in a sub-micron diffuser distribution unit,” stated Mr. Nick Havercroft, CEO, and Founder of Bioneb Pvt.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy